Xolair

Sanofi, Regeneron to seek FDA nod for Dupixent in hives disorder

Sanofi and Regeneron have presented data from a trial that could help push Dupixent across the FDA finish line to treat chronic spontaneous urticaria.

Kevin Dunleavy Sep 11, 2024 1:00am

FDA approves Roche, Novartis' Xolair for common food allergies

Feb 16, 2024 2:28pm

Roche's Xolair moves closer to food allergy approval from FDA

Dec 19, 2023 1:01pm

FDA rejects Sanofi, Regeneron's Dupixent to treat hives disorder

Oct 23, 2023 10:38am

Sanofi's Dupixent comes up short, stops hives trial

Feb 18, 2022 10:35am

Genentech, Novartis get FDA nod for self-injectable Xolair

Apr 16, 2021 1:15pm